Amiodarone Induced Organizing Pneumonia: A Masquerader of Community Acquired PneumoniaAna Vigário* and Catarina Mendonça
Hospital Centre of Oporto, Santo António Hospital, Internal Medicine Service, Oporto, Portugal
- *Corresponding Author:
- Ana Sofia Coutinho Vigário Rodrigues
Hospital Centre of Oporto, Santo António Hospital
Internal Medicine Service, Oporto-4050-637, Portugal
Tel: 00351 913091451
E-mail: [email protected]
Received date: January 20, 2016; Accepted date: January 27, 2016; Published date: January 31,2016
Citation: Vigário A, Mendonça C (2016) Amiodarone Induced Organizing Pneumonia: A Masquerader of Community Acquired Pneumonia. J Pulm Respir Med 6:319. doi:10.4172/2161-105X.1000319
Copyright: © 2016 Vigário A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Amiodarone is a widely used antiarrhythmic with well-known adverse effects, being pulmonary toxicity one of the most serious, occurring even with low doses. Amiodarone-induced organizing pneumonia (AIOP) is an infrequent histopathological presentation but a few cases have been reported in the literature.
A 78-year-old woman with atrial fibrillation doing amiodarone 200 mg once daily for two years was admitted to the Emergency Department with progressive dyspnea to rest, productive purulent cough, flulike symptoms and pleuritic chest pain. Blood tests revealed a hypoxemic respiratory failure and a systemic inflammatory response, and the chest radiography showed bilateral, multifocal pulmonary infiltrates. Microbiologic studies of urine, blood and sputum were sterile. The patient was initially treated for community acquired pneumonia, with clinical and radiological worsening despite multiple extended spectrum antibiotics. The complementary study excluded other etiologies, and a transthoracic pulmonary biopsy was performed, revealing histology consistent with organizative pneumonia.
AIOP is typically presented as a community acquired pneumonia that does not respond to antibiotics. The diagnosis depends on a high clinical suspicion, and compatible clinical and radiological pattern. Although it is not the most frequent, the presented case enforces the assumption that toxicity is present even with lower doses such as 200 mg once daily for 2 years.